Combination therapy with midostaurin improves survival of AML patients with FLT3 mutations, phase 1

(Dana-Farber Cancer Institute) A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology’s annual meeting on Monday, Dec. 7.

source : www.eurekalert.org

Related News:

• ACC: Triglycerides Decreased with Rosuvastatin Therapy
• "Healthy" Snacks Loaded with Sugar and Salt
• Children with chronic respiratory illness are vulnerable to critical H1N1
• AAOS: Long-Term Benefit of Spine Fracture Tx Cited (CME/CE, with video)
• No Increased Risk of Death with ‘The Pill’
• Movement disorder symptoms are lessened by an antibiotic: Treating worms with ampicillin helps restore normal movement
• Docs Often Miss Lipid Targets, More So with Women (CME/CE)
• Kids’ Flu Shots Stop Community Transmission (CME/CE, with audio)
• Elevated Levels Of Cobalt And Chromium Found In Offspring Of Moms With Metal-on-Metal Hip Implants
• Guide Dogs Granted Permission To Apply For Judicial Review In Dispute With Royal Borough Of Kensington And Chelsea Over Plans For Exhibition Road, UK